Quality Assurance Development

HONG BIAN

** ********* *****

Holmdel, NJ *****

732-***-**** ************@*****.***

RESEARCH SCIENTIST

Research Scientist with eleven years of extensive experience in

Pharmaceutical industry with expertise in Immunology, Cell and Molecular

Biology, Biochemistry, with unique ability to develop technical solutions

to complex problems. Extensive hands-on experience in techniques such as

RNA/DNA isolation, molecular cloning, production of monoclonal antibodies,

small animal handling, western blotting, ELISA, compound efficacy profiling

and assay development, viral based gene delivery, real-time qPCR, gene

silencing by RNA interference, cell culture, recombinant DNA technologies

and method development and validation under cGMP environment. Highly

motivated, productive, logical and known as a good team player.

TECHNICAL SKILLS

Compound screening

IMAP assay, Leadseeker, GTP?s assay for GPCR, Membrane and whole cell

binding, FLIPR assay, HTRF assay, TR-FRET, Alphascreen (Sure-Fire assay)

Molecular Biology

Gene cloning, GST-fusion protein construction, expression, purification and

characterization, Bacteria transformation, cell line transfection,

Baculovirus expression system, RNA analysis, RT-PCR, real-time PCR, Primer

and probe design, Northern blot, Southern blot, Probe labeling (radioactive

and non-radioactive), Plasmid construction, subcloing and restriction

enzyme mapping, siRNA

Protein Chemistry

Purification of proteins and antibodies by affinity chromatography using

traditional column methods and automated HPLC, Immunoprecipitation, SDS-

PAGE gel and Western blot

Immunochemistry

Flow cytometry, Immunofluorescence labeling of cells, ELISA,

characterization of monoclonal antibodies

Cell Biology

Cell culture of different cell lines (small and large scales), Generation

of Hybridomas from Immunized Mice, Signal transduction study, Cell

proliferation assay, Isolation of different cell types from human and

animal blood, Chemotaxis

PROFESSIONAL EXPERIENCE:

PURDUE, Cranbury, NJ

Feb, 2012 - Jun, 2013

Cell Biologist (contract)

. Study -Opioid Receptor mediated Extracellular Signal-Regulated Kinases

(ERKs) phosphorylation and signal transduction mechanism.

. Developed phospho-ERK Alphascreen assay.

MERCK, Kenilworth, NJ 2009 - 2011, 12

Scientist II

. Produced and evaluated anti-phospho-IRAK-4 antibodies, maintained anti-

phospho-IRAK-4 hybridomas, tested hybridoma supernatant by ELISA.

. Supported TyK2 program, evaluated the effects of JAK and TyK2 SiRNA on

pSTAT3,5 of different cell lines by Sure-Fire assay.

. Developed HTRF assays for phospho-BTK and phospho-PLC gamma2 detection

in Ramos cell line.

. Developed and validated BTK Target Engagement assay to support the

discovery of BTK inhibitors.

. Presented work at group meetings, company-wide forums and scientific

conferences.

HONG BIAN

Page Two

732-***-**** ************@*****.***

SCHERING-PLOUGH, Kenilworth, NJ 2000 - 2009

Scientist II

. Supported CXCR2 compound evaluations for the identification of backup

candidate.

. Supported RLC recommendation of TACE inhibitors, determined TACE

inhibitor Ki and IC50 values of lead TACE inhibitors in MMP1, 2, 3, 7, 9,

13, 14 and ADAM10 assays for selectivity, study TACE compound potency

shift.

. Developed JAK-3 screening assays for FLASH and FLASH JAK3 hit follow-up.

. Conducted Lead ID and Lead OP program of Interleukin-1 receptor-

associated kinases (IRAK4).

. Developed strategy, designed and executed experiments to identify and

understand markers of small and biological molecule drug activity in

biochemical and cell based assays.

. Screened and monitored perspective compounds for CCR7 program.

. Supported CCR2 MCP-1-Ig optimization program and MIP-3?-Ig program.

. Carried out GPCR counter screening to support company's GPCR program.

. Developed a CXCR5 HTS assay for flash screening.

. Studied inhibition of Human Phosphodiesterease.

. Revised and modified SOPs for various established protocols.

UCLA SCHOOL OF MEDICINE, Los Angeles, CA 1999 - 2000

Immogenetics Center, Department of Pathology & Laboratory Medicine

Academic Specialist

. Set up and managed research lab. Produced and evaluated anti-HLA Class I

antibody.

. Studied signal transduction mechanism of endothelial cells and smooth

muscle cells via anti-HLA Class I antibody.

. Supported all phases of grant renew process.

COLUMBIA UNVERSITY, New York, NY 1991 - 1999

Division of Immunogenetics, Department of Pathology College of Physicians &

Surgeons

Staff Associate

. Studied expression of T-cell receptor VB genes in allopeptide-specific T-

cell.

. Studied the correlation between T cell growth in biopsy and rejection in

transplanted heart, and T cell receptor VB genes expression in T cell

which grow from biopsy of transplanted heart.

. Cloned, expressed and purified HLA-DR protein in Baculovirus expression

system.

. Studied signal transduction mechanism of endothelial cell and smooth

muscle cell via anti-HLA ClassI antibody.

. Key Person of research grant NIH- RO1-AI/HL 42819-01A1 and Grant-In-Aid,

American Heart Association (Anti-HLA Antibody Mediated Endothelial Injury

in Cardiac Transplantation).

EDUCATION

Master of Science, School of Public Health, Columbia University, New York,

NY

Bachelor of Medicine, West China University of Medical Science, Chengdu,

China

PROFESSIONAL DEVELOPMENT

Drug Development Certificate, Quality Assurance/Regulatory Affairs Program

School of Pharmacy, Temple University, PA

ACHIEVEMENTS AND AWARDS

ASHI Scholar Award, American Society for Histocompatibility and

Immunogenetics, 1999

ASHI Scholar Award, American Society for Histocompatibility and

Immunogenetics, 1996

HONG BIAN

Page Three

732-***-**** ************@*****.***

Bibliography

Original Research Articles

1. Gonsiorek W, Hesk D, Kinsley D, Chen SC, Fine JS, Jackson JV, Bober LA,

Deno G, Hong Bian, Lunn CA, Kozlowski JA, Lavey B, Piwinski J, Narula SK,

Lundell DJ, Hipkin RW. (2006) Characterization of peripheral human

cannabinoid receptor (hCB2) expression and pharmacology using a novel

radioligand, [35S]SCH225336. J Biol Chem. 2006 Sep 22;281(38):28143-51

2. Dwyer, Bian, Hipkin et al. TBD "Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-

[[(R)-1-(5- methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-

enylamino}-benzamide (Sch527123), an orally bioavailable, CXCR2/CXCR1

receptor antagonist" J. Med. Chem. 2006, 49(26), 7603-7606

3. Hong Bian, Ji Zhang, Ping Wu, Lori A. Varty, Yanlin Jia, Todd Mayhood,

John A. Hey, Peng Wang. Differential type 4 cAMP-specific

phosphodiesterase (PDE4) expression and functional sensitivity to PDE4

inhibitors among rats, monkeys and humans. Biochemical Pharmacology, 2004

Dec 1; 68(11):2229-36

4. Peng Wang, Ji Zhang, Hong Bian, Ping Wu, Reshma Kuvelkar, Ted T. Kung,

Yvette Crawley, Robert W. Egan & M. Motasim Billah. Induction of

lysosomal and plasma membrane-bound sialidases in human T cells via T

cell receptor. Biochem. J. 2004 Jun 1; 380 (Pt2): 425-33

5. H. Bian, E. F. Reed. Anti-HLA class I antibodies transduce signals in

endothelial cells resulting in FGF receptor translocation, down-

regulation of ICAM-1 endothelial and cell proliferation. Transplantation

Proceedings, 33(1-2): 311, 2001

6. H. Bian, and E. F. Reed. Alloantibody mediated signal transduction in

endothelial cells and smooth muscle cells; enhancement by TNF-? and INF-

?. J. Immunol. 163:1010-1018, 1999.

7. N. Nath, H. Bian, E.F. Reed, S.P. Chellapan. HLA class I- mediated

induction of cell proliferation involves cyclin E-mediated inactivation

of Rb function and induction of E2F activity. J. Immunology, 162:5351-

5358, 1999.

8. Bian, H., and E.F. Reed. Anti-HLA antibodies transduce proliferative

signals in endothelial cells and smooth muscle cells. Transplant. Proc.,

31, 1924, 1999.

9. Bian, H., Harris, P.E, and Reed, E. F. Ligation of HLA class I molecules

on smooth muscle cells with anti-HLA antibodies induces tyrosine

phosphorylation, FGF receptor expression and cell proliferation.

International Immunology, 10:1315-1323, 1998.

10. Harris, P.E., Bian, H., and Reed, E.F. Induction of High Affinity FGF

Receptor expression and proliferation in human endothelial cells by anti-

HLA antibodies: A possible mechanism for transplant atherosclerosis.

Journal of Immunology, 159:5697-5704,1997.

11. Bian, H., Harris, P.E., Mulder, A. and Reed, E.F. Anti-HLA antibody

ligation to HLA class I molecules expressed by endothelial cells

stimulates tyrosine phosphorylation, inositol phosphate generation, and

proliferation. Human Immunol., 53,90-97, 1997.

12. Reed, E.F., Hong, B., Ho, E., Harris, P.E., Weinberger, J. and Suciu-

Foca, N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies

identifies heart allograft recipients at risk of transplant associated

coronary artery disease. Transplantation 61:1-7, 1996.

13. Liu, Z., Sun, Y.K., Xi, Y.P, Hong, B., Harris, P.E., Reed, E., and

Suciu-Foca, N. Limited usage of TCR V? genes by allopeptide specific T

cells. J. Immunology. 150:3180-3186, 1993.

14. Harris, P.E., Lupu, F., Hong, B., Reed, E.F. and Suciu-Foca, N.

Differentiation-stage specific self peptides bound by major

histocompatibility complex class I molecules. J. Exp. Med. 177:783-790,

1993.

Contact this candidate